Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Short-term Investments: 2021-2025

Historic Short-term Investments for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $42,859.

  • InMed Pharmaceuticals' Short-term Investments fell 0.80% to $42,859 in Q3 2025 from the same period last year, while for Sep 2025 it was $42,859, marking a year-over-year decrease of 0.80%. This contributed to the annual value of $43,384 for FY2025, which is 0.74% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Short-term Investments of $42,859 as of Q3 2025, which was down 1.21% from $43,384 recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Short-term Investments peaked at $46,098 during Q1 2022, and registered a low of $40,582 during Q1 2025.
  • Moreover, its 3-year median value for Short-term Investments was $43,064 (2024), whereas its average is $42,895.
  • Its Short-term Investments has fluctuated over the past 5 years, first climbed by 3.27% in 2023, then dropped by 8.27% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Short-term Investments (Quarterly) stood at $45,424 in 2021, then declined by 5.22% to $43,053 in 2022, then climbed by 3.27% to $44,462 in 2023, then decreased by 8.27% to $40,787 in 2024, then decreased by 0.80% to $42,859 in 2025.
  • Its Short-term Investments was $42,859 in Q3 2025, compared to $43,384 in Q2 2025 and $40,582 in Q1 2025.